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Objective. Nowadays numerous ancillary techniques detecting HPV DNA and mRNA compete with cytology; however no perfect
test exists; in this study we evaluated classification and regression trees (CARTs) for the production of triage rules and estimate
the risk for cervical intraepithelial neoplasia (CIN) in cases with ASCUS+ in cytology. Study Design. We used 1625 cases. In
contrast to other approaches we used missing data to increase the data volume, obtain more accurate results, and simulate real
conditions in the everyday practice of gynecologic clinics and laboratories. The proposed CART was based on the cytological
result, HPV DNA typing, HPV mRNA detection based on NASBA and flow cytometry, p16 immunocytochemical expression, and
finally age and parous status. Results. Algorithms useful for the triage of women were produced; gynecologists could apply these
in conjunction with available examination results and conclude to an estimation of the risk for a woman to harbor CIN expressed
as a probability. Conclusions. The most important test was the cytological examination; however the CART handled cases with
inadequate cytological outcome and increased the diagnostic accuracy by exploiting the results of ancillary techniques even if there
were inadequate missing data. The CART performance was better than any other single test involved in this study.
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1. Introduction
Cervical cancer (CC) is the third most common cancer and
the fourth leading cause of cancer death in females worldwide
[1].More than 85%of these cases and deaths are in developing
countries; this is due to lack of screening that may allow
detection of precancerous and early stage cervical cancer.
Despite the advances in screening, cervical cancer remains a
serious problem of public health even in developed countries,
due to the high percentage of detection failures [2].
CC is known to be caused almost always by human papil-
lomavirus (HPV) infection which is the commonest sexually
transmitted infection worldwide. About 100 types of HPV
virus that can infect humans have been identified. Among
them, 15 are oncogenic and can cause CC. Improved under-
standing of HPV infection and the natural history of cervical
neoplasia have resulted in the addition of the HPV DNA test
along with the Pap test and frequently a competing test.
Nowadays, ancillary techniques for CC screening are
available.These includeHPVDNA typing andmRNA identi-
fication of the viral E6/E7 oncogenes that are linked to onco-
genic activation. Among them, mRNA typing with nucleic
acid based amplification (NASBA) [3] and mRNA-Flow-
FISH techniques in screening programs produced promising
results in increasing PPV and reducing unnecessary recalls
and referrals to colposcopy [4–7]. At the same time, it was
reported that the immunocytochemical detection of p16 can
increase the diagnostic accuracy of the Pap test [8].
Several published studies in the literature attempted to
clarify the role of each technique as a unique test to substitute
the Pap test [3–7, 9–17]. By the detailed analysis of these,
it can be concluded that the performance measures of the
methods under control differ significantly, affected by the
disease incidence and the prevalence of HPV infection in the
population study group; thus, application of a single method,
even if it offers a level of protection, does not determine
reliably the risk for individual women to harbor cervical
intraepithelial neoplasia (CIN). However, from the meta-
analysis of published studies [9–12] it is evident that the
sensitivity of Pap test combined with the HPV DNA test is
higher than the sensitivity of each individual method.
Computer science and artificial intelligence enabled the
development of computer assisted systems for the support
of clinical diagnosis or therapeutic and treatment decisions.
Various classification techniques such as neural networks
[18–29], discriminant analysis [18, 30–32], classification and
regression trees (CARTs) [33–35], or genetic algorithms [36]
have been used in medicine. The application of new molec-
ular techniques that are nowadays used in the diagnostic
cytology laboratory [37] improves the accuracy of the final
diagnosis in comparison to that of cytology alone.
Among the various decision support techniques (CARTs)
is an attractive statistical approach to extract knowledge from
data as they are straightforward to construct and easily under-
standable by physicians. The application of these systems
produces simple decision algorithms linkedwith probabilities
that can be promising to define triage rules and perhaps give
a better understanding of the disease.
The aim of this study was to investigate the potential role
ofCARTs applied on various diagnostic variablesmeasured in
themodern cytopathology laboratory and to build algorithms
for the triage of individual cases. Special focus was given to
design the study as pragmatic as possible: thus, (1) cases from
two different parts of the country were selected, (2) a part of
the cases were considered to be negative as no histological
confirmation could be obtained due to ethical reasons, and
(3) inadequate test results (i.e., missing data) were included
as this is the cytopathology laboratory reality.
2. Materials and Methods
2.1. Involved Institutes and Ethics. Our study involved the 3rd
Department of Obstetrics and Gynecology, the Department
of Cytopathology and the 2nd Department of Pathology, all
three hosted in “Attikon”University Hospital, Medical School
of Athens University, and the Department of Obstetrics
and Gynecology of University Hospital of Ioannina City.
The study was approved by the University Hospital Ethics
Boards and participating women signed an informed consent
(ICON) form to allow use of their epidemiologic, diagnostic,
and ancillary test data.
2.2. Cytology. All cytological and ancillary examinations
were based on ThinPrep liquid based cytology (LBC) mate-
rial obtained before colposcopical examination. The smears
were routinely prepared for cytological examination and the
remaining material in the ThinPrep vial was used for addi-
tional evaluation of biomarkers related to the HPV lifecycle.
The smears were assessed by experienced cytopathologists.
Histological material was obtained during colposcopy and/or
during treatment by conization. The obtained histological
samples were fixed and prepared according to standard
histopathology protocols.
The cytological findings for each woman were formu-
lated according to the revised Bethesda classification system
(TBS2001 system) [38, 39].
2.3. Histological Confirmation. The histological diagnosis
was the golden standard andwas used as the target category of
each woman. Punch biopsies were performed by experienced
colposcopists (in practice for more than 10 years) as part of
the study protocol. The three-tiered cervical intraepithelial
neoplasia grading system was used for reporting histological
diagnosis. Clinically negative (CN) cases were included in the
study. These were defined as CN if the cytology, colposcopy,
and the CLARTHuman Papillomavirus 2HPVDNA test (see
Section 2.4) were all negative. Despite the lack of histological
biopsies due to ethical hurdles, these women were included
and analyzed in a target category of less than CIN2. The
correlation of the cytological results in relation to histology
is presented in Table 1.
2.4. Molecular Tests. In relation to the HPV lifecycle bio-
markers we used (a) HPV DNA typing using the CLART
Human Papillomavirus 2 (GENOMICA) kit for the simul-
taneous detection of 35 different HPV genotypes by PCR
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Table 1: Correlation of the cytological with the histological diagnosis.
Histological result Subtotal
CN Negative CIN 1 CIN 2 CIN 3 SCC ADENO-CA
Cytology
Inadequate — 10 29 9 9 2 2 61
Negative 619 62 67 5 2 — — 755
ASC-US — 37 109 18 5 — — 169
LGSIL — 36 259 50 15 — 1 361
ASC-H — 6 6 2 3 2 1 20
HGSIL — 10 40 75 94 9 2 230
SCC — — — — 1 15 2 18
ADENO-CA — — — — — 1 10 11
Total 619 161 510 159 129 29 18 1625
amplification of a fragment within the highly conserved L1
region of the virus [40]; (b) NASBA assays [41] (NucliSENS
EasyQ HPV v1.0) that were used for the identification of
E6/E7 mRNA of the HPV types: 16, 18, 31, 33, and 45; (c)
the PermiFlow (Invirion Diagnostics, LLC, Oak Brook, IL)
kit for the identification of E6/E7 mRNA expression of high
risk HPV using flow cytometry [6]; and (d) the immunocy-
tochemical expression of p16 using the CINtec Cytology Kit
[42]. In addition to puremedical data, epidemiologic features
were involved as well, specifically woman age and parous
status.
Within the clinical laboratory, it is not infrequent that
an ancillary test produces invalid results or the biological
material that remains in the vial is not adequate to perform
additional tests; therefore, it is not guaranteed that there are
available sets of such data for all women participating in the
study. Additionally parous details were not available for all
women as such data oftenwere not considered important and
referral forms were incomplete.
2.5. Golden Standard. Our target was to classify each woman
into one of the following categories: (a) <CIN2, which
included the histologically negative andCIN-1 cases as well as
the CN cases, and (b) ≥CIN2, which included the histological
categories: CIN-2, CIN-3, SCC, and ADENO-CA.
2.6. Data Formulation. For each case, a vector of 50 variables
was created (Table 2); this had the result of the cytological
examination expressed according to the Bethesda system.
Results of the HPV DNA test examination were expressed as
35 individual values (either positive or negative), one for each
HPV DNA genotype; additionally, in relation to the found
subtypes five other variables were investigated: the existence
of high risk, low risk, or any type as well as the number
of high risk and the number of low risk types that were
identified. For the NASBA HPV mRNA typing, we used the
result for each individualHPV type (16, 18, 31, 33, and 45).The
result of the PermiFlow test was involved using twomethods,
either as a percentage or as positive or negative (the cut-off
value to assign a flow cytometry result was 1.5%); in addition,
the result of the immunocytochemical expression of p16 was
included. Finally, two other variables were entered to the tree
construction process: woman age and parous status. For all
variables, if there were no data, the value was left blank or
declared inadequate indicating that there was no valid result
or there was not adequate material in the ThinPrep vial to
perform additional examinations.
2.7. Statistical Techniques and Modeling. The CART model
was created using IBM SPSS Statistics 19 for Windows (SPSS
Inc., Chicago, USA). The CART algorithm is possible to be
configured and use a specific feature at the first node of the
tree; however, in this study CART was allowed to select as
first test the test with the highest overall accuracy. To assess
the performance, various statistical measures were extracted:
specificity, sensitivity, positive and negative predictive value
(PPV and NPV), false positive and false negative rates (FPR
and NPR), and overall accuracy (OA).
3. Results
In total 1006 histologically confirmed cases (161 without
evidence of CIN or malignancy, 510 CIN-1, 159 CIN-2,
129 CIN-3, and 47 cervical cancer cases (29 squamous cell
carcinomas (SCC) and 18 adenocarcinomas (ADENO-CA)))
were included in this study and additionally 619 CN cases.
The correlation of the cytological versus the histological
outcome of our material appears in Table 1. In our material,
the percentage of valid data (i.e., after excluding inadequate,
invalid, and unsatisfactory results) was for the cytologi-
cal examination 96.25%, for ARRAYS 91.94%, for NASBA
67.75%, for flow cytometry 81.54%, and for p16 68.68%.
For the construction of the CART model, the CHAID
algorithm was used; the CART architecture was 20-5-10; that
is, each parent node was forced to 20 or more vectors, and
each terminal node had more than 5 vectors, and the tree
depthwas not allowed to growmore than 10 levels.The system
was pruned to obtain simpler forms, the significance level for
splitting a node was set to 0.05, the chi-square statistic was
based on the likelihood ratio and the significance values were
adjusted using the Bonferroni method, resplitting of merged
categories within one node was allowed, the age and flow
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Table 2: Variables entered to the model.
Variable name Description Value range
Cytology
The result of the cytological
examination expressed according to
the Bethesda 2009 system
WNL, ASC-US, LGSIL, ASC-H, HGSIL, SCC,
ADENO CA, and <blank> if there is no result
HPV DNA arrays
A6, A11, A16, A18, A26, A31, A33, A35, A39,
A40, A42, A43, A44, A45, A51, A52, A53, A54,
A56, A58, A59, A61, A62, A66, A68, A70, A71,
A72, A73, A81, A82, A83, A84, A85, and A89
The existence of individual subtypes
according to the arrays examination
0 if the specific subtype is not found
1 if the specific subtype is found
<blank> if there is no result
Has HR Positive if one or more high risksubtypes were found during typing Positive, negative, or missing
Has LR Positive if one or more low risksubtypes were found during typing Positive, negative, or missing
Has any type Positive if one or more subtypes werefound during typing Positive, negative, or missing
No HR The number of high risk subtypes thatwere found during typing An integer or missing
No LR The number of low risk subtypes thatwere found during typing An integer or missing
N16, N18, N31, N33, and N45 The result of the E6/E7 mRNA test forthe specific HPV subtype
0 if negative
1 if positive
<blank> if there is no result
Flow
The result of the identification of
E6/E7 mRNA expression of high risk
HPV using flow cytometry technique
0 if negative (<1.5%)
1 if positive (>1.5%)
<blank> if there is no result
Flow %
The result of E6/E7 mRNA expression
of high risk HPV using flow cytometry
technique expressed as a percentage
A number or <blank> if there is no result
p16 The result of the p16immunocytochemical examination
0 if negative
1 if positive
<blank> if there is no result
Age The woman age at the time ofexamination A positive number
Parous Woman parous status 1 if she has born one or more children and 0 ifnot
percentage intervals were set to 10 (i.e., flow and age values
had 10 levels), and finally the maximum number of iterations
was 500.
The CART architecture appears in Figure 1. It is worth
noting that the role of the cytological examination result
is dominant and that characteristics, such as the woman’s
age and the majority of HPV subtypes as were identified by
the HPV subtyping test, were not found significant to be
included. An example of a method of tree usage in practice
is as follows.
(i) The user starts from the top node and examines the
value of the proposed characteristic, in our case the
cytological examination outcome.
(ii) According to the value the user navigates to the
appropriate node; in our case if the cytological exam-
ination is inadequate, we examine the flow result and
a negative result leads the user to a probability for the
case to be benign equal to 93.9% while if there is no
result or the outcome of flow cytometry is positive
then the user may examine the existence on HPV
subtype 16 within the mRNA test, and interestingly a
negative result provides a probability for malignancy
equal to 93.8% as 15 out of the 16 cases with this profile
were ≥CIN2 in histology.
(iii) During navigation to the tree, the user may choose to
stay in the proposed node if he/she is satisfied by the
risk danger (probability) otherwise may examine the
next proposed feature to find a more accurate result.
(iv) The steps are repeated down to the terminal nodes if
the user is not satisfied from the proposed risk levels
from the previous parent nodes.
In a second example, the user may start with a negative
cytological examination result; according to the lab perfor-
mance, the probability for such a case to be positive is very
small (0.9%). However, if more guarantees are required for
this result, an HPV DNA test may be performed, a positive
outcome on HPV subtype 16 reduces the probability of a
case to be less than CIN-2 from 99.1% to 66.7% (4 out
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p<CIN-2 = 100.0%
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p<CIN-2 = 90.0%
<CIN2
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p≥CIN-2 = 78.3%
≤1.7
Figure 1: Structure of the CART model.
of the 12 cases with negative cytology and positive HPV
DNA subtype 16 were finally found histologically CIN-2 or
worst), and a negative or invalid result on test for HPV
subtype 16 combinedwith a negative result for flow cytometry
practically assures the woman that the probability to have a
lesion worse than CIN-2 is negligible, as 568 cases with this
profile in our material had less than CIN-2 and no case was
found with equal or more than CIN-2 lesion.
A third example is related to the cases that are ASC-
US or LGSIL in cytology; if the triage is based only on the
cytological examination, all these women should be referred
to colposcopy. However, in our material 441 cases were
<CIN2 and 89 were ≥CIN2 (in total 530 women); thus, the
probability to have <CIN2 is 83.2%, and if additional material
is available in the vial, then a flow examination may be
more helpful for the triage; in particular, a negative result
in the flow examination gives a probability for <CIN2 equal
to 96.5%, while a positive result indicates that this woman
has more chances to harbor ≥CIN2 (46.1% Figure 1), and
in such case these women could be immediately referred to
colposcopy.This approach would allow reduction of referrals
to colposcopy by 257, in more detail from 530 to 273;
therefore, about half of the women (51.51%) could avoid
immediate referral to colposcopy.
The assignment matrix of CART results appears in
Table 3; actually the system classified 1216 out of the 1290
<CIN2 cases and 279 out of the 335 ≥CIN2 cases, and
the statistics show that the model had sensitivity: 83.28%,
specificity: 94.26%, PPV: 79.04%, NPV: 95.60%, FPR: 5.74%,
FNR: 16.72%, and OA: 92.00%. In order to assess the CART
Table 3: CART results.
Actual category Predicted category Grand total
<CIN 2 ≥CIN 2
<CIN 2 1216 74 1290
≥CIN 2 56 279 335
Grand total 1272 353 1625
performance in relation to the performance of each individ-
ual examination, the related statistics were extracted.
Specifically in Table 4 are summarized the performance
metrics of the CART model, of the cytological examination
using the ASC-US cases as a cutoff (i.e., all cases that were
ASC-US and above in cytology were considered positive
and referred to colposcopy) and similarly using an ASC-H
cytological outcome as cutoff. For the HPV DNA typing,
three alternative methods were evaluated: a woman was
considered to be at risk and referred to colposcopy if (1) any
HPV type was found, (2) only if a high risk type was found,
and (3) only if 16 or 18 subtypes were identified. Finally, in
Table 4 are presented the performance metrics for mRNA
test using NASBA or flow cytometry and p16; that is, a case
was considered to be at risk if any subtype was found in the
NASBA examination or if a flow cytometry result was positive
or screening of a p16 slide gave a positive result.
Finally in order to allow a more detailed evaluation of
the methodology, in Table 5 are summarized the results of
the histological outcome (blocks of rows) along with the
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Table 4: Performance of CART and individual examinations.
CART
Cytology
using
cutoff
ASC-US+
Cytology
using
cutoff
ASC-H+
Arrays
(positive if
any type
was found)
Arrays
(positive if a
high risk type
was found)
Arrays
(positive if
subtype 16 or
18 was found)
NASBA
(positive if
any type
was found)
Flow cytometry
(positive if the
result is positive
>1.5%)
p16
Sensitivity 83.28% 97.76% 69.33% 87.71% 84.72% 52.82% 69.65% 88.19% 57.21%
Specificity 94.26% 59.79% 95.04% 70.49% 75.02% 90.28% 87.09% 79.60% 93.57%
PPV 79.04% 37.82% 77.78% 42.86% 46.11% 57.82% 62.15% 48.49% 69.68%
NPV 95.60% 99.07% 92.53% 95.79% 95.11% 88.35% 90.41% 96.87% 89.44%
FPR 5.74% 40.21% 4.96% 29.51% 24.98% 9.72% 12.91% 20.40% 6.43%
FNR 16.72% 2.24% 30.67% 12.29% 15.28% 47.18% 30.35% 11.81% 42.79%
OA 92.00% 67.39% 89.90% 73.96% 76.97% 82.73% 83.02% 81.13% 86.11%
Valid results 1625 1564 1564 1494 1494 1494 1101 1325 1116
% of valid
results 100.00% 96.25% 96.25% 91.94% 91.94% 91.94% 67.75% 81.54% 68.68%
cytological categories to which the cases were assigned (rows)
in combination with the CART model outcome (columns).
4. Discussion and Conclusions
Test Papanicolaou is viewed as the most successful CC test
[43] if it is repeatedly applied. However, CC is not yet
eliminated even in countries with well-organized cervical
cancer screening programs.There are many available options
for the application of biomarkers in the triage of abnormal
cases [17, 44–51]; however, these are either highly sensitive
or highly specific, but not both at the same time. Nowadays,
there is no consensus for the optimal management of women
with abnormal Pap smears and equally not infrequently
womenwith negative cytology are found to have a high-grade
lesion ≥CIN2 histologically. Women with an ASC-US result
in cytology present more complex management problems.
The widely accepted management options of such cases are
either immediate referral to colposcopy or surveillance with
repeated Pap tests. The first option can overload colposcopy
clinics and may lead to overintervention and overtreatment
due to subtle findings. Overtreatment commonly has neg-
ative psychological effects with increasing anxiety and may
further increase the risk for long-term perinatal morbidity
in subsequent pregnancies [52]. Conversely, repeat cytology
with surveillance has an inherent risk of missing HGSILs,
dependent on the laboratory performance, has the risk of
poor compliance, and may inversely increase the psychologi-
cal burden for women with cytological abnormalities that are
not further assessed. It is clear that we need more accurate
diagnostic tools in order to limit the number of unnecessary
colposcopic referrals without compromising the detection of
high-grade disease.
In our material the percentage of ≥CIN2 cases in the
total of the cases given as ASC-US was 23/169 = 13.61%.
Furthermore, the percentage of ≥CIN2 cases in the total of
LgSIL cases was 66/361 = 18.28%. Both percentages are in
agreement with those reported by other researchers [53] that
range between 5–17% and 9–16%, respectively, in the pub-
lished literature. On the other hand, the percentage of cases
given in cytology as HGSIL and found histologically lower
than CIN2 was 50/230 = 21.74%. This is also consistent with
the rates published in the literature [54, 55], demonstrating
an agreement across various study settings.
Exploitation of ancillary test data for improvement of cer-
vical intraepithelial lesions is nowadays a hot research topic
with important applications. Since 2010, theHellenic Cervical
Pathology (HeCPA) Study Group is working on innovative
approaches that use advanced mathematical and computing
tools for the exploitation of ancillary tests that are nowadays
available. Up to now, preliminary results are presented in the
literature [35, 56]. In our previously published study [35],
we applied CART models based on a smaller dataset, using
cases that had valid examination results for all the available
ancillary tests. This approach had clearly the disadvantage of
a reduced usable data volume and does not capture the real
life situation, that is, missing values. In addition, parameters
related to woman history and demographic data were not
included and the probabilities for a woman to harbor CIN
were not calculated for each tree part. In two other published
reports [56, 57] by the same group, there were applied neural
networks to solve the same problem; the disadvantage of
these approaches was again the requirement to have complete
data for each series and no risk estimation was performed.
In this study, we exploited the CART ability to handle cases
with missing data and therefore increase the power of the
study. The probability for each individual part of the tree was
extracted. We used additional information related to women
and concluded that parous is an important factor. We also
extracted knowledge from our dataset in the form of triage
algorithms that not only could be useful to the decision-
makers towards their requests for ancillary tests but also
promote a scoring system classifying individual women as
high, low, or middle risk.
According to our results, despite the multitude of fea-
tures entered into the CART model (Table 2), the training
algorithm identified as useful only a small number of those
parameters and was finally included in the CART model
(Figure 1). The major discriminating characteristic was the
cytological diagnosis; in relation to typing, only the existence
BioMed Research International 7
Table 5: CART results in relation to the cytological outcome and the histological result.
Histology Cytology CART result Grand total
Correct False negative False positive
CN Negative 619 619
(CN) Total 619 619
Negative
Inadequate 10 10
Negative 62 62
ASC-US 36 1 37
LGSIL 36 36
ASC-H 3 3 6
HGSIL 2 8 10
Negative total 149 12 161
CIN 1
Inadequate 25 4 29
Negative 67 67
ASC-US 107 2 109
LGSIL 242 17 259
ASC-H 2 4 6
HGSIL 5 35 40
CIN 1 total 448 62 510
CIN 2
Inadequate 8 1 9
Negative 5 5
ASC-US 7 11 18
LGSIL 26 24 50
ASC-H 2 2
HGSIL 75 75
CIN 2 total 118 41 159
CIN 3
Inadequate 8 1 9
Negative 2 2
ASC-US 2 3 5
LGSIL 8 7 15
ASC-H 3 3
HGSIL 94 94
SCC 1 1
CIN 3 total 116 13 129
SCC
Inadequate 2 2
ASC-H 2 2
HGSIL 9 9
SCC 15 15
ADENO-CA 1 1
SCC total 29 29
ADENO-CA
Inadequate 2
LGSIL 1 1
ASC-H 1 1
HGSIL 2 2
SCC 2 2
ADENO-CA 10 10
ADENO-CA total 16 2 18
Grand total 1495 56 74 1625
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of any high risk and of individual subtypes 16 and 62 was
found important in our dataset and especially subtype 62
was a discriminating factor for a small number of cases. In
relation to E6 and E7 expression, it was found that the flow
cytometry results expressed both as positive/negative and as
a percentage as well as the subtype 31 from the NASBA exam-
ination were important. Moreover, the immunocytochemical
expression of p16 and parous data also appeared in the CART
branches.
Based on the results, the proposed methodology had
superior performance in relation to the overall accuracy
(92.00%) than the majority of alternative methods (Table 4).
There was marginal statistically significant difference only
between CART and the cytology with ASC-H+ threshold
(𝜒2 = 4.027,𝑃 = 0.0448). However, for all other comparisons,
the differences in the overall accuracy were statistically
significant, specifically CART against cytology with ASC-
US+ threshold (𝑃 < 0.0001), arrays using any type (𝑃 <
0.0001), arrays using high risk subtypes (𝑃 < 0.0001), arrays
for subtype 16 or 18 (𝑃 < 0.0001), NASBA for any type
(𝑃 < 0.0001), and finally p16 (𝑃 < 0.0001). In relation
to the comparison of the CART model and the cytological
examination with threshold ASC-H+, the sensitivity of the
CARTmodel (83.28%) was significantly higher than cytology
(69.33%); therefore, the proposed method had significantly
(𝑃 < 0.0001) better performance than all other alternatives.
In relation to the false positive cases, the CART wrongly
categorized 74 cases as positive (≥CIN2); from these 12
were negative and 62 CIN-1 in histology, although 50 of
these cases were given as ASC-H or HGSIL in cytology
(Table 5), 17 as LGSIL, 3 as ASC-US, and the remaining 4 as
inadequate in cytology. No case was cytologically negative,
as the cytological result is the primary characteristic that
is considered as important by our methodology, and these
results were expected. The FPR of the CART model was
5.74%, outperformed only by the cytological result with ASC-
US+ cutoff (2.24%) but at the cost of specificity (94.26 versus
59.79%; see Table 4).
The analysis of false negative cases is more important; the
CARTmodel gave 56 false negative cases in total (14 ASC-US,
32 LGSIL, 2 inadequate, 7 negative in cytology, and 1 ASC-
H; see Table 5). None of these cases had HGSIL or cancer as
cytological result.The histological outcome of these cases was
41 CIN-2, 13 CIN-3, and 2 adenocarcinomas. The cytological
result for the last 2 cases was ASCH and LGSIL and there was
additionally colposcopical agreement.
In relation to the 61 samples that were inadequate in
cytology (Table 5), 22were≥CIN2, among them4 carcinomas
(2 adenocarcinomas and 2 SCC), 9 CIN-2, and 9 CIN-3,
and the remaining 39 cases were <CIN2; the CART model
classified correctly 54 of them (35<CIN2, 8 CIN-2, 8 CIN-3, 2
SCC, and 2 adenocarcinomas) and missed 6 cases (4 CIN-1, 1
CIN-2, and 1 CIN-3). It is worth noting that this decision was
based only on biomarker data and parous status. Therefore,
the number ofwomen thatwould require a second cytological
examination could be reduced dramatically.
Concluding the application of the proposed method gave
encouraging results and not only could be helpful towards
a better management of women for various findings during
cytological examination but also provides a flexible technique
for the estimation of ≥CIN2 risk. As a result, the proposed
method provides a guide towards personalized management
and therapeutic decisions, may reduce the overload of col-
poscopy clinics and unnecessary treatments, and identifies
a higher percentage of women at risk of cervical cancer or
precancerous lesions.
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